Altered Serum IgG Levels to α-Synuclein in Dementia with Lewy Bodies and Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Natural self-reactive antibodies in the peripheral blood may play a considerable role in the control of potentially toxic proteins that may otherwise accumulate in the aging brain. The significance of serum antibodies reactive against α-synuclein is not well known. We explored serum IgG levels to monomeric α-synuclein in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) with a novel and validated highly sensitive ELISA assay. Antibody levels revealed stark differences in patients compared to healthy subjects and were dependent on diagnosis, disease duration and age. Anti-α-synuclein IgG levels were increased in both patient groups, but in early DLB to a much greater extent than in AD. Increased antibody levels were most evident in younger patients, while with advanced age relatively low levels were observed, similar to healthy individuals, exhibiting stable antibody levels independent of age. Our data show the presence of differentially altered IgG levels against α-synuclein in DLB and AD, which may relate to a disturbed α-synuclein homeostasis triggered by the disease process. These observations may foster the development of novel, possibly preclinical biomarkers and immunotherapeutic strategies that target α-synuclein in neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972
Lee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877 · cited 1×
“neurons to astroglial cells and may promote a local inflammatory response [19].”
BackgroundGlial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701 · cited 5×
“Because of the relative abundance of activated cytokine producing APCs such as microglia and macrophages in afflicted nervous system tissue [26,27], it is reasonable to assume that an adaptive immune response would result in the production of antibodies against a-synuclein, which may ideally be characteristic for a pa…”
BackgroundInfluentialSchulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627 · cited 1×
“and deposit in the nervous system in the form of oligomers or insoluble amyloid [32–34].”
BackgroundPathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders
Jucker, M., & Walker, L. C. (2011) · Annals of Neurology · doi:10.1002/ana.22615 · Cited by 622
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542 · cited 1×
“the mouse model Lewy body pathology could be prevented by active immunization with a-synuclein or direct transfer of antibodies against a-synuclein [24,25].”
BackgroundTokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425 · cited 1×
“Increasingly, a-synuclein, a protein involved in synaptic plasticity and neurotransmission, is being explored as an additional CSF biomarker, and evidence may point to lower levels in Parkinson’s disease (PD) patients compared to controls [5,7–9].”
BackgroundMollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382 · cited 1×
“The biochemical markers Amyloid beta (Ab) 1–42 and tau in the cerebrospinal fluid (CSF), that are decreased and elevated in AD, respectively, offer reasonable sensitivity and specificity for the diagnosis of AD, especially if analyzed together, however, their ability to differentiate AD from other forms of dementia, s…”
BackgroundAntibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
Bae, E.-J., Lee, H.-J., Rockenstein, E., Ho, D.-H., Park, E.-B., Yang, N.-Y., Desplats, P., Masliah, E., & Lee, S.-J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1292-12.2012 · Cited by 339
Rogers, J., Mastroeni, D., Leonard, B., Joyce, J., & Grover, A. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(07)82012-5 · Cited by 260
Lewy Body Pathology in Alzheimer's Disease
Kotzbauer, P. T., Tojanowski, J. Q., & Lee, V. M. V. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:225 · Cited by 177 · cited 1×
“In addition, there is considerable clinical and pathological overlap between the two disorders [3].”
BackgroundYanamandra, K., Gruden, M. A., Casaite, V., Meskys, R., Forsgren, L., & Morozova-Roche, L. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018513 · Cited by 171 · cited 2×
“detected elevated antibody levels against a-synuclein in patients with PD [12–14].”
BackgroundAltered lymphocyte distribution in Alzheimer’s disease
RICHARTZSALZBURGER, E., BATRA, A., STRANSKY, E., LASKE, C., KOHLER, N., BARTELS, M., BUCHKREMER, G., & SCHOTT, K. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.01.010 · Cited by 167
Self-citation
Cited by
Sengupta, U., & Kayed, R. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102270 · Cited by 293
Shalash, A., Salama, M., Makar, M., Roushdy, T., Elrassas, H. H., Mohamed, W., El-Balkimy, M., & Abou Donia, M. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00720 · Cited by 58
Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer’s disease
McIntyre, J. A., Ramsey, C. J., Gitter, B. D., Saykin, A. J., Wagenknecht, D. R., Hyslop, P. A., & Initiative, F. T. A. D. N. (2015) · Autoimmunity · doi:10.3109/08916934.2015.1008464 · Cited by 22
“These data indicate that the humoral immune system is active within the neuropil, and that antibodies readily cross the blood brain barrier (BBB) [27] between the CNS and the blood.”
Do human B-1 lymphocytes truly exist?
Martínez-Gutiérrez, M. I., Cañedo-Solares, I., Gómez-Chávez, F., Molina-López, L. M., Flores-Rabasa, R., Magdaleno-Villanueva, J. A., León-Pedroza, J. I., & Correa, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1810144 · Cited by 2
“In addition, healthy individuals have NatAbs against autoantigens without known prior exposure, such as human amyloid peptide (83, 84), tumor-associated antigens (33, 85), mutant huntingtin (86), and a -synuclein (87).”
Metadata
- Authors
- Koehler, N. K. U., Stransky, E., Shing, M., Gaertner, S., Meyer, M., Schreitmüller, B., Leyhe, T., Laske, C., Maetzler, W., Kahle, P., Celej, M. S., Jovin, T. M., Fallgatter, A. J., Batra, A., Buchkremer, G., Schott, K., & Richartz-Salzburger, E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-31
- Volume
- 8
- Issue
- 5
- Pages
- e64649
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2014102001
- Cited by
- 35
- References
- 17
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.